Soft-tissue sarcomas (STS) represent a complex group of neoplasms of mesenchymal origin with an incidence of about 1% among all human malignancies ([@bib31]). The clinical implications of STS are disproportional to their frequency, and their medical management is challenging ([@bib2]). Despite several improvements in early diagnosis, surgical techniques, and radio- and chemotherapy, this disease remains a threat to life for many patients. The high mortality is related to tumour progression and complications of distant metastasis. Currently, the prediction of disease progression is limited to the use of clinical and histopathological factors, including age at diagnosis, tumour size, histologic grade, histologic subtype, tumour depth, tumour site, and margin status ([@bib20]). New prognostic markers are needed to allow a strategy for stratifying patients with STS for risk of tumour recurrence to provide individual adjuvant therapy and follow-up schedules. Various molecular biomarkers have been intensively investigated to predict clinical outcome in cancer patients, but excessive costs and technical factors preclude their clinical use ([@bib3]; [@bib13]; [@bib34]).

Recent data indicate that inflammatory cells that accumulate around neoplasms (e.g., in oesophageal, gastric, colorectal, cervical, ovarian, bladder, pancreatic, prostate, and non-small cell lung cancer) have a crucial role in tumour progression and its prognosis ([@bib7]; [@bib25]). For example, patients with a high density of lymphocytes in the stroma of tumours were reported to have a better clinical outcome compared with those with a low density of lymphocytes, whereas a high density of neutrophils was associated with poor clinical outcome ([@bib5]; [@bib33]). The systemic inflammatory response also causes changes in the levels of circulating white blood cells, including neutrophils and lymphocytes. However, day-dependent fluctuations in the number of neutrophils are not always in line with those of lymphocytes ([@bib32]). Hence, the relative value of a combined index using neutrophil and lymphocyte counts in form of a neutrophil to lymphocyte (N/L) ratio can more accurately reflect fluctuations between neutrophils and lymphocytes to reflect the antitumour efficacy of the host immune system more precisely. To date, N/L ratio was identified as a prognostic marker in many types of cancer including gastrointestinal tract malignancies, non-small cell lung cancer, cervical carcinoma, hepatocellular carcinoma, pancreatic and ovarian cancer, showing a consistently decreased survival in patients presenting with a high N/L ratio ([@bib12]; [@bib4]; [@bib27]; [@bib1]; [@bib19]; [@bib22]; Mallappa *et al*, 2012). However, there is little information on the influence of the preoperative N/L ratio on clinical outcome in STS patients ([@bib14]). Predicting survival of cancer patients by determining the N/L ratio, which can be measured relatively simple and cost-effective from peripheral blood, might be helpful in patient stratification and individual risk assessment.

The aim of the current study was to assess the predictive value of preoperative N/L ratio for time to tumour recurrence (TTR) and overall survival (OS) in a large cohort of STS patients with curative surgical resection.

Materials and methods
=====================

Subjects
--------

In all, 260 patients with histologically confirmed STS, which have been operated between March 1998 and November 2010 at the Department of Orthopaedic Surgery, Medical University of Graz, were included in this retrospective study. Follow-up was performed until November 2012. All patients were included in the follow-up programme of the Department of Orthopaedic Surgery and the Division of Clinical Oncology, Department of Medicine, Medical University of Graz, providing follow-up examinations in regular intervals (3-month intervals in years 1--3, 6-months intervals in years 4--5, and 12-month intervals in years 6--15 after diagnosis). Follow-up investigations included clinical check-up and radiological analyses (computed tomography, magnetic resonance imaging, abdominal ultrasound, chest X-ray, or computed tomography). Follow-up data of all patients were available.

Clinical information including treatment scheme (surgery, radio- and chemotherapy) and histopathological diagnosis including tumour grade were retrospectively obtained from the patient\'s history. Surgical margins were determined as wide or marginal according to [@bib10]. For the present study, all histologic specimens were centrally re-reviewed by an independent experienced pathologist (BL-A) specialised in diagnosing STS at the Institute of Pathology, Medical University of Graz. All sarcomas were diagnosed according to the current WHO classification soft tissue and bone tumours ([@bib11]). Tumours were graded according to the French Federation of Cancer Centres Sarcoma Group (FNCLCC) grading system ([@bib6]) or tumour grade was defined by tumour entity. Malignant fibrous histiocytomas have been re-classified according to the current diagnostic criteria ([@bib11]; [@bib23]).

This study has been approved by the Institutional Review Board (IRB) of the Medical University of Graz (25-050 ex 12/13).

Statistical analysis
--------------------

The primary end point of the study was TTR. Time to tumour recurrence was calculated from the date of diagnosis of STS to the date of the first observation of tumour recurrence. It was censored at the time of death or at the last follow-up if the patient remained tumour recurrence-free at that time. The secondary end point was OS. Overall survival was determined from the date of diagnosis to the date of death of any cause. The optimal cutoff values for the N/L ratio were calculated by applying receiver operating curve (ROC) analysis.

The N/L ratio was correlated with clinical and histopathological data by chi square (*χ*^2^) test. The association between clinical and histopathological parameters and N/L ratio with TTR and OS was analysed using Kaplan--Meier curves and compared by the log-rank test. In the multivariate Cox-regression analysis, the model was adjusted for prognostic factors significantly associated with end points in univariate analysis. Hazard ratios (HRs) estimated from the Cox analysis were reported as relative risks with corresponding 95% confidence intervals (CIs). All analyses were performed using the SPSS statistical software package (SPSS Inc., Sunnyvale, CA, USA). A two-sided *P*\<0.05 was considered as statistically significant.

Results
=======

Baseline patient characteristics, tumour biological factors, and therapy modalities are shown in [Table 1](#tbl1){ref-type="table"}. The median age at time of diagnosis was 59 years (range 18--96 years). The median follow-up time was 50 months (range 0--120 months (censored)). The included histologic diagnoses are summarised in [Table 2](#tbl2){ref-type="table"}. Applying ROC analysis the optimal cutoff value for N/L ratio was 3.45 for TTR (AUC: 0.616, 95%CI=0.547--0.677) and 3.58 for OS (AUC: 0.676, 95%CI=0.611--0.736).

In univariate analysis, we found a significant association between tumour grade, tumour necrosis and adjuvant radio- and chemotherapy and TTR and between tumour grade, tumour necrosis, tumour stage and adjuvant chemotherapy and OS ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}). In multivariate analysis, we observed a significant association between tumour necrosis and adjuvant chemotherapy and TTR and between tumour necrosis and tumour stage and OS ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}).

An elevated N/L ratio was significantly associated with tumour size ⩾5 cm and the presence of histopathological tumour necrosis (*P*=0.019 and *P*=0.001), respectively. None of the other clinicopathological parameters was associated with an N/L ratio of ⩾3.45 (data not shown).

Of the 260 STS patients, 9 (3.5%) were metastasised at diagnosis and 41 (15.8%) developed metastatic disease within 10 years follow-up period. Eighty-six (33.1%) patients died within 10 years follow-up period. Among the 260 STS patients, metastatic disease was diagnosed in 23 of 148 (15.5%) patients with an N/L ratio of \<3.45 and in 23 of 80 (28.8%) patients with an N/L ratio of ⩾3.45 (*P*\<0.018). Regarding OS, death occurred in 35 of 156 (22.4%) patients with N/L ratio \<3.58 and in 37 of 72 (51.4%) patients with N/L ratio ⩾3.58 (*P*\<0.001).

In univariate analysis, elevated preoperative N/L ratio was significantly associated with decreased TTR (HR, 2.32; 95%CI, 1.30--4.14; *P*=0.005) ([Table 3](#tbl3){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}) and remained significant in the multivariate analysis including tumour grade, tumour necrosis, and adjuvant radio- and chemotherapy (HR, 1.98; 95%CI, 1.05--3.71; *P*=0.035) ([Table 3](#tbl3){ref-type="table"}). Patients with N/L ratio ⩾3.45 showed a median TTR of 77.9 months. In contrast, patients with N/L ratio \<3.45 had a median TTR of 99.1 months. In univariate analysis, elevated N/L ratio was also significantly associated with decreased OS (HR, 2.90; 95%CI, 1.82--4.61; *P*=0.001) ([Table 4](#tbl4){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}) and remained significant in multivariate analysis including tumour grade, tumour stage, tumour necrosis, and adjuvant chemotherapy (HR, 1.88; 95%CI, 1.14--3.12; *P*=0.014) ([Table 4](#tbl4){ref-type="table"}). Patients with N/L ratio ⩾3.58 presented with a median OS of 60.5 months, whereas patients with N/L ratio \<3.58 showed a median OS of 93.2 months.

In subgroup analyses of the four major histologic types (myxofibrosarcoma, liposarcoma, leiomyosarcoma, and synovial sarcoma), we found a significant association between elevated N/L ratio and decreased TTR in myxofibrosarcoma and between elevated N/L ratio and decreased OS in myxofibrosarcoma and liposarcoma in univariate analysis ([Tables 5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"}). In multivariate analysis, the result remained statistically significant for liposarcoma and OS ([Table 6](#tbl6){ref-type="table"}).

Discussion
==========

In the present study, we showed that elevated preoperative N/L ratio in the peripheral blood is associated with decreased TTR and OS in STS patients following curative surgery.

It has been widely established that the ability of tumours to progress and metastasize is not only dependent on the intrinsic characteristics of tumour cells, but also on the tumour microenvironment. The tumour environment that is influenced by inflammatory cells including leukocytes is responsible for the inflammatory response and supports proliferation, survival, and migration of tumour cells through the inhibition of apoptosis, promotion of angiogenesis, and damage of DNA ([@bib15]; [@bib16]; [@bib7]; [@bib25]). The systemic inflammatory reaction results in neutrophilia and relative lymphocytopenia, measurable in the peripheral blood ([@bib18]; [@bib5]; [@bib33]). In recent years, there has been increasing evidence that high N/L ratio correlates with poor clinical outcome in patients with various cancers after tumour resection. In colorectal cancer, increased preoperative N/L ratio was identified as an independent factor predicting tumour recurrence following curative surgery (Mallappa *et al*, 2012). [@bib27] reported that an increased preoperative N/L ratio was associated with higher tumour stage and remained an independent predictor of survival after complete resection for primary lung cancer. In uterine sarcomas, the N/L ratio was shown to be more useful than serum CA 125 for the preoperative differentiation of uterine sarcomas from benign tumours ([@bib21]). [@bib4] observed that an elevated N/L ratio may predict an adverse outcome in ovarian cancer. In STS, only one study indicated an association between the N/L ratio and disease-specific outcome, suggesting worse outcome in patients with elevated pretreatment N/L ratio. This study, however, included only 83 STS patients, had a relative short follow-up period and analysed only OS, which might be influenced by other non-tumour related factors, as the main clinical end point ([@bib14]).

A definitive explanation underlying these findings has not been clearly elucidated yet. Several possible reasons for the association between elevated N/L ratio and poor survival in cancer patients have been postulated. First, the high N/L ratio reflects an enhanced neutrophil response to tumours. In a mouse model, tumour cells secreted chemotactic cytokines, inflammatory proteins, and interleukins to recruit neutrophils to the tumour microenvironment ([@bib17]). Neutrophils have been reported to stimulate tumour angiogenesis by producing proangiogenic factors, including growth factors, chemokines, and proteases, hence promoting tumour progression ([@bib29]; [@bib8]; [@bib28]). Furthermore, neutrophils may suppress the immune system. They have been shown to inhibit the cytolytic activity of lymphocytes, natural killer cells, and activated T cells ([@bib26]; [@bib9]; [@bib30]). Second, elevated N/L ratio reflects a relative lymphopenia. Lymphocytes are known to act as the host defense against tumour. They have a major role in cytotoxic cell death and cytokine production that inhibit proliferation and migration of tumour cells ([@bib7]; [@bib25]). Systemic inflammation results in the secretion of inhibitory immunologic mediators, inducing immunosuppression due to impaired lymphocyte function ([@bib25]). This process leads to a poorer lymphocyte-mediated antitumour cellular immune response, indicated by increased T8-suppressor lymphocytes and decreased T4-helper lymphocytes ([@bib25]). The N/L ratio, in fact, reflects a balance between pro-tumour inflammatory status and antitumour immune status. This balance seems to be shifted in favour of pro-tumour inflammatory status in cancer patients with elevated N/L ratio and thus poor outcome.

In the present study, we also found a significant association between an elevated N/L ratio and tumour size of ⩾5 cm and the presence of histopathological tumour necrosis. Since the elevated N/L ratio and tumour necrosis were both significantly associated with clinical outcome, we hypothesise that the high N/L ratio may reflect the presence of tumour necrosis. In the subgroup analyses of the four major histologic entities, an elevated N/L ratio was associated with decreased clinical outcome in myxofibrosarcoma and liposarcoma. The lack of association between the N/L ratio and clinical outcome in leiomyosarcoma and synovial sarcoma may be due to the small sample size.

The strength of this study is definitely the large sample size and the long follow-up period. However, there are also some limitations, mostly arising from the retrospective study design and a mixture of various histologic subtypes of STS. Nevertheless, as STSs are rare and heterogenous tumours, pooling of different histologic subtypes by tumour grade is well established in studies on prognosis in patients suffering from STS.

In conclusion, the presented results indicate that an elevated preoperative N/L ratio in the peripheral blood is independently associated with poor clinical outcome in STS patients undergoing curative tumour resection. Validation studies or large scaled prospective studies are warranted to verify our findings.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
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###### Baseline patient characteristics

                               ***N***  **%**
  --------------------------- --------- -------
  **Sex**                               
  Male                           141    54.2
  Female                         119    45.8
  **Tumour site**                       
  Trunk                          24     9.2
  Extremities                    236    90.8
  **Tumour grade**                      
  G1                             43     16.5
  G2                             54     20.8
  G3                             161    61.9
  Unknown                         2     0.8
  **Tumour size**                       
  \>5                            174    66.9
  ⩽5                             63     24.2
  Unknown                        23     8.8
  **Tumour depth**                      
  Superficial                    65     25
  Deep                           185    71.2
  Unknown                        10     3.8
  **Tumour necrosis**                   
  None                           112    43.1
  \<50%                          86     33.1
  ⩾50%                           59     22.7
  Unknown                         3     1.2
  **Surgical margins**                  
  Wide                           242    93.1
  Marginal                       18     6.9
  **Tumour stage**                      
  Localised at diagnosis         251    96.5
  Metastasised at diagnosis       9     3.5
  **Adjuvant radiotherapy**             
  Yes                            167    64.2
  No                             89     34.2
  Unknown                         4     1.5
  **Adjuvant chemotherapy**             
  Yes                            35     13.5
  No                             218    83.8
  Unknown                         7     2.7

Abbreviation: *N*=number.

###### Histologic type

                                              ***N***   **%**
  ------------------------------------------ --------- -------
  Myxofibrosarcoma                              76      29.2
  **Liposarcoma**                                      
  Well differentiated                           26       10
  Myxoid                                        20       7.7
  Pleomorphic                                   13        5
  Leiomyosarcoma                                32      12.3
  Synovial sarcoma                              28      10.8
  Pleomorphic sarcoma                           19       7.3
  Malignant peripheral nerve sheath tumour      10       3.8
  Spindle cell sarcoma NOS                       8       3.1
  Epithelioid sarcoma                            8       3.1
  Dermatofibrosarcoma protuberans                6       2.3
  Pleomorphic rhabdomyosarcoma                   4       1.5
  Angiosarcoma                                   3       1.2
  Fibrosarcoma                                   2       0.8
  Myxoid chondrosarcoma                          2       0.8
  Malignant mesenchymoma                         2       0.8
  Alveolar soft part sarcoma                     1       0.4

Abbreviation: *N*=number; NOS=not otherwise specified.

###### Univariate and multivariate analysis of association of prognostic factors and N/L ratio with time to tumour recurrence

                               **Univariate analysis**   **Multivariate analysis**                       
  --------------------------- ------------------------- --------------------------- -------------------- -------
  **Sex**                                                                                                
  Female                            1 (referent)                   0.593                1 (referent)      0.924
  Male                           1.165 (0.66--2.04)                                  1.03 (0.57--1.85)       
  **Tumour site**                                                                                        
  Extremities                       1 (referent)                   0.827                1 (referent)      0.400
  Trunk                          1.093 (0.49--2.43)                                  1.42 (0.63--3.20)       
  **Tumour depth**                                                                                       
  Superficial                       1 (referent)                   0.987                1 (referent)      0.636
  Deep                            1.01 (0.52--1.94)                                  0.85 (0.44--1.66)       
  **Tumour grade**                                                                                       
  G1                                1 (referent)                   0.040                1 (referent)      0.156
  G2                              0.16 (0.04--0.67)                                  3.81 (0.80--18.11)      
  G3                              1.00 (0.54--1.88)                                  2.37 (0.51--11.02)      
  **Tumour size**                                                                                        
  \<5 cm                            1 (referent)                   0.169                1 (referent)      0.322
  ⩾5 cm                           1.67 (0.81--3.50)                                  1.47 (0.69--3.12)       
  **Tumour necrosis**                                                                                    
  0                                 1 (referent)                   0.001                1 (referent)      0.037
  ⩽50%                            2.67 (1.32--5.41)                                  1.96 (0.95--4.04)       
  \>50%                           3.99 (1.88--8.46)                                  3.00 (1.28--7.01)       
  **Resection margins**                                                                                  
  Wide                              1 (referent)                   0.971                1 (referent)      0.637
  Marginal                        1.02 (0.37--2.83)                                  1.29 (0.44--3.78)       
  **Tumour stage**                                                                                       
  Localised at diagnosis                 NA                         NA                       NA            NA
  Metastasised at diagnosis                                                                                  
  **Adjuvant chemotherapy**                                                                              
  Yes                               1 (referent)                  \<0.001               1 (referent)      0.005
  No                              3.01 (1.69--5.39)                                  1.16 (0.55--2.44)       
  **Adjuvant radiotherapy**                                                                              
  Yes                               1 (referent)                   0.047                1 (referent)      0.692
  No                              1.97 (1.01--3.86)                                  1.16 (0.55--2.44)       
  **N/L ratio 3.45**                                                                                     
  \<3.45                            1 (referent)                   0.005                1 (referent)      0.035
  ⩾3.45                           2.32 (1.30--4.14)                                  1.98 (1.05--3.71)       

Abbreviations: CI=confidence interval; HR=hazard ratio; NA=not applicable; N/L=neutrophil/lymphocyte.

###### Univariate and multivariate analysis of association of prognostic factors and N/L ratio with overall survival

                              **Univariate analysis**   **Multivariate analysis**                       
  --------------------------- ------------------------- --------------------------- ------------------- -------
  **Sex**                                                                                               
  Female                      1 (referent)              0.364                       1 (referent)        0.035
  Male                        0.82 (0.53--1.26)                                     0.62 (0.39--0.97)    
  **Tumour site**                                                                                       
  Extremities                 1 (referent)              0.877                       1 (referent)        0.592
  Trunk                       1.05 (0.54--2.04)                                     1.21 (0.62--2.35)    
  **Tumour depth**                                                                                      
  Superficial                 1 (referent)              0.986                       1 (referent)        0.632
  Deep                        1.00 (0.60--1.65)                                     0.88 (0.53--1.49)    
  **Tumour grade**                                                                                      
  G1                          1 (referent)              \<0.001                     1 (referent)        0.098
  G2                          2.06 (0.72--5.84)                                     1.98 (0.60--6.59)    
  G3                          5.78 (2.32--14.41)                                    2.66 (0.84--8.47)    
  **Tumour size**                                                                                       
  \<5 cm                      1 (referent)              0.282                       1 (referent)        0.381
  ⩾5 cm                       1.35 (0.78--2.35)                                     1.29 (0.73--2.27)    
  **Tumour necrosis**                                                                                   
  0                           1 (referent)              \<0.001                     1 (referent)        0.001
  ⩽50%                        2.42 (1.34--4.40)                                     1.47 (0.73--2.95)    
  \>50%                       6.02 (3.36--10.78)                                    3.00 (1.40--6.45)    
  **Resection margins**                                                                                 
  Wide                        1 (referent)              0.811                       1 (referent)        0.850
  Marginal                    0.90 (0.36--2.22)                                     1.09 (0.43--2.76)    
  **Tumour stage**                                                                                      
  Localised at diagnosis      1 (referent)              \<0.001                     1 (referent)        0.020
  Metastasised at diagnosis   1.48 (1.22--1.80)                                     1.29 (1.04--1.61)    
  **Adjuvant chemotherapy**                                                                             
  Yes                         1 (referent)              0.028                       1 (referent)        0.505
  No                          1.65 (1.06--2.57)                                     1.17 (0.74--1.87)    
  **Adjuvant radiotherapy**                                                                             
  Yes                         1 (referent)              0.691                       1 (referent)        0.406
  No                          1.10 (0.69--1.75)                                     0.80 (0.48--1.35)    
  **N/L ratio 3.58**                                                                                    
  \<3.58                      1 (referent)              \<0.001                     1 (referent)        0.014
  ⩾3.58                       2.90 (1.82--4.61)                                     1.88 (1.14--3.12)    

Abbreviations: CI=confidence interval; HR=hazard ratio; N/L=neutrophil/lymphocyte.

###### Univariate and multivariate analysis of association of prognostic factors and N/L ratio with time to tumour recurrence in specific histologic tumour types

                         **Univariate analysis**   **Multivariate analysis**                         
  ---------------------- ------------------------- --------------------------- --------------------- -------
  **Myxofibrosarcoma**                                                                               
                         1 (referent)              0.008                       1 (referent)          0.141
                         3.98 (1.44--11.00)                                    2.51 (0.74--8.50)      
  **Liposarcoma**                                                                                    
                         1 (referent)              0.375                       1 (referent)          0.404
                         2.97 (0.29--33.03)                                    4.88 (0.12--201.66)    
  **Leiomyosarcoma**                                                                                 
                         1 (referent)              0.469                       1 (referent)          0.553
                         1.76 (0.38--8.09)                                     2.12 (0.18--25.35)     
  **Synovial sarcoma**                                                                               
                         1 (referent)              0.106                       1 (referent)          0.214
                         5.97 (0.68--52.20)                                    7.46 (0.31--178.03)    

Abbreviations: CI=confidence interval; HR=hazard ratio; N/L=neutrophil/lymphocyte.

###### Univariate and multivariate analysis of association of prognostic factors and N/L ratio with overall survival in specific histologic tumour types

                         **Univariate analysis**   **Multivariate analysis**                          
  ---------------------- ------------------------- --------------------------- ---------------------- -------
  **Myxofibrosarcoma**                                                                                
                         1 (referent)              0.007                       1 (referent)           0.441
                         3.64 (1.43--9.24)                                     1.52 (0.53--4.36)       
  **Liposarcoma**                                                                                     
                         1 (referent)              0.028                       1 (referent)           0.014
                         5.36 (1.19--24.08)                                    16.60 (1.78--154.62)    
  **Leiomyosarcoma**                                                                                  
                         1 (referent)              0.070                       1 (referent)           0.381
                         2.60 (0.92--7.31)                                     1.82 (0.48--6.91)       
  **Synovial sarcoma**                                                                                
                         1 (referent)              0.066                       1 (referent)           0.110
                         3.79 (0.92--5.66)                                     5.56 (0.68--45.67)      

Abbreviations: CI=confidence interval; HR=hazard ratio; N/L=neutrophil/lymphocyte.
